Sana Biotechnology, Inc.

SANA Nasdaq CIK: 0001770121

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 188 EAST BLAINE STREET, SUITE 350, SEATTLE, WA,
Mailing Address 188 EAST BLAINE STREET, SUITE 350, SEATTLE, WA,
Phone (206) 701-7914
Fiscal Year End 1231
EIN 831381173

Financial Overview

FY2025

$256.01M
Total Liabilities
$-0.96
EPS

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report April 8, 2026 View on SEC
3 Initial insider ownership report March 27, 2026 View on SEC
4 Insider stock transaction report March 10, 2026 View on SEC
4 Insider stock transaction report March 10, 2026 View on SEC
4 Insider stock transaction report March 6, 2026 View on SEC
4 Insider stock transaction report March 6, 2026 View on SEC
4 Insider stock transaction report March 4, 2026 View on SEC
10-K Annual financial report March 3, 2026 View on SEC
8-K Current report of material events March 3, 2026 View on SEC
3 Initial insider ownership report February 18, 2026 View on SEC

Annual Reports

10-K March 3, 2026
  • Initiated a Phase 1 clinical trial for its lead *in vivo* gene therapy candidate, SC291, with initial patient dosing expected in early 2026.
  • Filed an Investigational New Drug (IND) application for its first hypoimmune cell therapy candidate, SC451, for oncology applications, paving the way for potential clinical trials in 2026.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.